Cardiology

Cardiac specialists discuss improvement in health status with different treatments for hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, and Martin S. Maron, MD comment on the role of mavacamten in oHCM as seen in the EXPLORER-HCM trial.

Childhood BMI, SBP, and total cholesterol level among those risk factors associated with adult cardiovascular events.

Steve R. Ommen, MD, discusses the use of novel agents in the pipeline for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

A systematic review and meta-analysis of more than 70 RCTs details a J-shape dose-response relationship between omega-3 fatty acid consumption and blood pressure, with 2-3 grams per day considered the optimal dose for blood pressure lowering.

Steve R. Ommen, MD, leads a discussion on factors to consider when choosing treatment for hypertrophic cardiomyopathy (HCM).

Experts in cardiology review invasive treatments, challenges with HCM treatments, and how to optimize treatment for patients.

Drs Javed Butler, Martin S. Maron, Steve R. Ommen, and James Januzzi provide insight on approaching treatment of HCM with pharmacologic and nonpharmacologic interventions.

Steve R. Ommen, MD; and Martin S. Maron, MD, review the role of AHA/ACC guidelines, imaging techniques, and circulating biomarkers in approaching the diagnosis and treatment of hypertrophic cardiomyopathy.

John A. Spertus, MD, MPH, comments on the effect of oHCM on health status and quality of life for patients.

Drs Steve R. Ommen, Martin S. Maron, John A. Spertus, Javed Butler, and James Januzzi provide insight on the presentation of nonobstructive and obstructive hypertrophic cardiomyopathy.

An analysis of data from more than 75,000 patients with diabetic kidney disease details the risk of fracture among new users of SGLT2 inhibitors compared to new users of DPP-4 inhibitors.

Dr. Gregory Weiss breaks down a recent JAMA study that provides estimates of the impact over- and under-treatment with thyroid hormone treatment on cardiovascular disease risk in a cohort of US Veterans.

Screening and early-life interventions for these patients may prevent cardiometabolic outcomes, according to investigators.

Our endocrine month in review spotlights the most popular articles from the past month. This month's top articles include the approval of tirzepatide, news from AACE & ATTD, and a pair of podcast episodes.

Drs Patel and Bhatt discuss importance of correct dosing of direct oral anticoagulants in treatment of cardiovascular diseases.

Expert cardiologists provide an overview of dual pathway inhibition, modulation of thrombotic risk and treatment of CAD.

Data presented at SCAI 2022 detail trends in PCI during the COVID-19 pandemic. In this column, Dr. Gregory Weiss provides perspective on these trends and what it may mean for cardiologists going forward.

Using 21 years of follow-up data from more than 3000 patients with prediabetes, results of the DPPOS study demonstrate metformin use and lifestyle intervention reduced the risk of progressing to T2D, but did little to reduce the long-term risk of cardiovascular disease in these patients.

Data from an interim analysis of the DIPRA trial suggest distal radial artery access for cardiac catheterization and resulted in no significant differences in hand function compared to proximal radial artery access.

Long-term data from the SAFE-PAD trial at SCAI 2022 underlines the noninferiority of paclitaxel-coated devices versus non-drug-coat devices for use in patients with peripheral artery disease.

An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.

Chair of the SCAI's writing group for their 2022 guidelines on management of patent foramen ovale, Dr. Clifford Kavinsky, sits down with Practical Cardiology to take part in a Q&A on the guideline's recommendations and the writing process for the SCAI's first PFO guidance.

Dr Amy Pollak shares her thoughts on risk-benefit analysis when evaluating patients with high thrombotic/bleeding risk and treatment selection.

Dr Eric Secemsky discusses how use of stents has evolved over the years in treatment of polyvascular disease.